The role of aldosterone in hypertension;Aldosteron und hypertonie

Wiener Klinische Wochenschrift

Volumn 122, Issue 3-4, 2010, Pages 65-74

  Vonend, Oliver ^a   Quack, Ivo ^a   Rump, Lars Christian ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Adrenal vein sampling; Conn; Mineralocorticoid receptor antagonist; Primary hyperaldosteronism; Renin Angiotensin Aldosterone system

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; CYTOCHROME P450; CYTOCHROME P450 11B; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; MINERALOCORTICOID ANTAGONIST; RENIN; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ADDICTION; ADRENAL HYPERPLASIA; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; FAMILY HISTORY; HEART FAILURE; HYBRID GENE; HYPERALDOSTERONISM; HYPERTENSION; INCIDENTALOMA; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; POLYMERASE CHAIN REACTION; POTASSIUM BLOOD LEVEL; PRIMARY HYPERALDOSTERONISM; REVIEW; RISK ASSESSMENT; SCREENING;

HUMANS; HYPERALDOSTERONISM; HYPERTENSION;

EID: 77952471784     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-010-1313-5     Document Type: Review

References (69)

1. Conn JW (1955) Primary aldosteronism. J Lab Clin Med 45 (4): 661-664
2. Vasan RS, et al (2004) Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 351 (1): 33-41
3. Schlaich MP, et al (2002) Altered aldosterone response to salt intake and angiotensin II infusion in young normotensive men with parental history of arterial hypertension. J Hypertens 20 (1): 117-124
4. Sartori M, et al (2006) Aldosterone and refractory hypertension: a prospective cohort study. Am J Hypertens 19 (4): 373-379 (discussion 380)
5. Krum H, et al (2002) Efficacy of eplerenone added to reninangiotensin blockade in hypertensive patients. Hypertension 40 (2): 117-123
6. Chapman N, et al (2007) Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49 (4): 839-845
7. Lane DA, Shah S, Beevers DG (2007) Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 25 (4): 891-894
8. Saha C, et al (2005) Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 46 (3): 481-487
9. Sharabi Y, et al (2006) Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens 19 (7): 750-755
10. Schjoedt KJ, et al (2004) Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 47 (11): 1936-1939
11. Bomback AS, Klemmer PJ (2007) The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 3 (9): 486-492
12. Rump LC (2007) Secondary rise of albuminuria under AT1-receptor blockade - what is the potential role of aldosterone escape? Nephrol Dial Transplant 22 (1): 5-8
13. Kayes-Wandover KM, White PC (2000) Steroidogenic enzyme gene expression in the human heart. J Clin Endocrinol Metab 85 (7): 2519-2525
14. Takeda Y, et al (1996) Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 81 (8): 2797-2800
15. Pitt B, et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (10): 709-717
16. Pitt B, et al (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (14): 1309-1321
17. Loffing J, Korbmacher C (2009) Regulated sodium transport in the renal connecting tubule (CNT) via the epithelial sodium channel (ENaC). Pflugers Arch 458 (1): 111-135
18. White PC (2003) Aldosterone: direct effects on and production by the heart. J Clin Endocrinol Metab 88 (6): 2376-2383
19. Young MJ (2008) Mechanisms of mineralocorticoid receptor- mediated cardiac fibrosis and vascular inflammation. Curr Opin Nephrol Hypertens 17 (2): 174-180
20. Pitt B, et al (2003) Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108 (15): 1831-1838
21. Garnier A, et al (2004) Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 110 (13): 1819-1825
22. Bauersachs J, et al (2002) Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 39 (2): 351-358
23. Zhang ZH, et al (2002) The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure. Am J Physiol Heart Circ Physiol 283 (1): H423-433
24. Born-Frontsberg E, et al (2009) Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab 94 (4): 1125-1130
25. Buchner N, Vonend O, Rump LC (2006) Pathophysiology of hypertension: what's new? Herz 31 (4): 294-302
26. Sowers JR (2007) Metabolic risk factors and renal disease. Kidney Int 71 (8): 719-720
27. Sowers JR, Whaley-Connell A, Epstein M (2009) Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 150 (11): 776-783
28. Malik S, et al (2004) Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110 (10): 1245-1250
29. El-Gharbawy AH, et al (2001) Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension 37 (3): 845-850
30. Goodfriend TL, Egan BM, Kelley DE (1998) Aldosterone in obesity. Endocr Res 24 (3-4): 789-796
31. Cooper SA, et al (2007) Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 293 (4): H2009-2023
32. Epstein M (2006) Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 119 (11): 912-919
33. Russo P, et al (2002) Interaction between the C (-344)T polymorphism of CYP11B2 and age in the regulation of blood pressure and plasma aldosterone levels: cross-sectional and longitudinal findings of the Olivetti Prospective Heart Study. J Hypertens 20 (9): 1785-1792
34. Engeli S, Sharma AM (2001) The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. J Mol Med 79 (1): 21-29
35. Ehrhart-Bornstein M, et al (2003) Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A 100 (24): 14211-14216
36. Iacobellis G, Corradi D, Sharma AM (2005) Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med 2 (10): 536-543
37. Conn JW, et al (1965) Normokalemic primary aldosteronism. A detectable cause of curable "Essential" hypertension. JAMA 193: 200-206
38. Gordon RD (2004) Primary aldosteronism - actual epidemics or false alarm? Arq Bras Endocrinol Metabol 48 (5): 666-673
39. Lim PO, et al (2000) High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 14 (5): 311-315
40. Rossi GP, et al (2006) A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 48 (11): 2293-2300
41. Schwartz GL, Turner ST (2005) Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 51 (2): 386-394
42. Douma S, et al (2008) Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 371 (9628): 1921-1926
43. Mosso L, et al (2003) Primary aldosteronism and hypertensive disease. Hypertension 42 (2): 161-165
44. Young WF Jr (2003) Minireview: primary aldosteronism - changing concepts in diagnosis and treatment. Endocrinology 144 (6): 2208-2213
45. Sutherland DJ, Ruse JL, Laidlaw JC (1966) Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 95 (22): 1109-1119
46. Quack I, et al (2008) A tale of two patients with Mendelian hypertension. Hypertension 51 (3): 609-614
47. Vonend O, et al (2007) A German family with glucocorticoid- remediable aldosteronism. Nephrol Dial Transplant 22 (4): 1123-1130
48. Stowasser M, et al (1992) Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism. Clin Exp Pharmacol Physiol 19 (5): 319-322
49. Lafferty AR, et al (2000) A novel genetic locus for low rennin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22). J Med Genet 37 (11): 831-1815
50. So A, et al (2005) Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. J Hypertens 23 (8): 1477-1484
51. Newton-Cheh C, et al (2007) Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 49 (4): 846-856
52. Geller DS, et al (2008) A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 93 (8): 3117-3123
53. Funder JW, et al (2008) Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93 (9): 3266-3281
54. Schirpenbach C, et al (2009) The diagnosis and treatment of primary hyperaldosteronism in Germany: results on 555 patients from the German Conn Registry. Dtsch Arztebl Int 106 (18): 305-311
55. Reincke M, Seiler L, Rump LC (2003) Normokaliämischer primärer Hyperaldosteronismus. Dtsch Arztebl 100: A181-190
56. Willenberg HS, et al (2009) The serum sodium to urinary sodium to (serum potassium)2 to urinary potassium (SUSPPUP) ratio in patients with primary aldosteronism. Eur J Clin Invest 39 (1): 43-50
57. Pizzolo F, et al (2007) Laboratory diagnosis of primary aldosteronism, and drospirenone-ethinylestradiol therapy. Am J Hypertens 20 (12): 1334-2137
58. Stowasser M (2009) Update in primary aldosteronism. J Clin Endocrinol Metab 94 (10): 3623-3630
59. Vonend O, et al (2007) Comparison of adrenal imaging and selective adrenal vein sampling in primary hyperaldosteronism. Dtsch Med Wochenschr 132 (46): 2436-2441
60. Daunt N (2005) Adrenal vein sampling: how to make it quick, easy, and successful. Radiographics 25 [Suppl 1]: S143-158
61. Espiner EA, et al (2003) Predicting surgically remedial primary aldosteronism: role of adrenal scanning, posture testing, and adrenal vein sampling. J Clin Endocrinol Metab 88 (8): 3637-3644
62. Rossi GP, et al (2008) Adrenal vein sampling for primary aldosteronism: the assessment of selectivity and lateralization of aldosterone excess baseline and after adrenocorticotropic hormone (ACTH) stimulation. J Hypertens 26 (5): 989-997
63. Seccia TM, et al (2009) Adrenocorticotropic hormone stimulation during adrenal vein sampling for identifying surgically curable subtypes of primary aldosteronism: comparison of 3 different protocols. Hypertension 53 (5): 761-766
64. Jeunemaitre X, et al (1987) Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 60 (10): 820-825
65. Nadler JL, Hsueh W, Horton R (1985) Therapeutic effect of calcium channel blockade in primary aldosteronism. J Clin Endocrinol Metab 60 (5): 896-899
66. de Souza F, et al (2010) Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 55 (1): 147-152
67. de Gasparo M, et al (1987) Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 240 (2): 650-656
68. Mulder P, et al (2008) Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J 29 (17): 2171-2179
69. Jansen PM, van den Meiracker AH, Jan Danser AH (2009) Aldosterone synthase inhibitors: pharmacological and clinical aspects. Curr Opin Investig Drugs 10 (4): 319-326